Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 07:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue...
October 26, 2024 14:00 ET | Source: Apellis Pharmaceuticals, Inc.

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan,...
October 22, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third...
October 16, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Company to host a webinar on the detailed VALIANT results at 12:30 p.m. PT on Saturday, October 26 WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS)...
October 04, 2024 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
September 25, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on...
September 20, 2024 05:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
September 06, 2024 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant...
August 29, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences: ...
August 08, 2024 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all...